BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT)

PHARMACEUTICAL PREPARATIONS

BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) is listed on Nasdaq, where it has traded since August 12, 2025.

Listed On
Nasdaq
Listed Since
August 12, 2025
Employees
88
Market Cap
$224M

About BridgeBio Oncology Therapeutics, Inc. Common Stock

BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 62 institutions reported holding BBOT, with 58.9 million shares worth $449.2 million in aggregate. The largest reported holder was Cormorant Asset Management, with 17.9 million shares worth $136.2 million. Of the 5 largest holders listed below, all 5 held their positions unchanged during the quarter.

InstitutionSharesValueQuarter change
Cormorant Asset Management17,878,594$136MUnchanged
Deerfield Management Company4,885,446$37MUnchanged
Omega Fund Management3,289,661$25MUnchanged
Ecor1 Capital2,823,126$22MUnchanged
Alphabet2,823,126$22MUnchanged

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is BBOT?

BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) is listed on Nasdaq, where it has traded since August 12, 2025.

Who are the largest institutional holders of BBOT?

In 13F filings for the quarter ended June 30, 2026, the largest reported holders of BBOT were Cormorant Asset Management, Deerfield Management Company and Omega Fund Management.

How many institutions own BBOT?

62 institutions reported a position in BBOT for the quarter ended June 30, 2026, worth $449.2 million in total.

Did institutions buy or sell BBOT last quarter?

Of the 5 largest reported holders, all 5 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for BBOT.

Every reported institutional holder, plus insider and congressional trades in BBOT, on SentiSense.